The isomerase PIN1 controls numerous cancer-driving pathways and is a unique drug target

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Targeted cancer therapies face long-term ineffectiveness in solid tumors due to heterogeneous oncogenic pathway activation.
• Proline-directed phosphorylation is a common signaling mechanism in these pathways, regulated by kinases and phosphatases.
• Peptidyl-prolyl cis-trans isomerase (PIN1) regulates the structure and function of phosphorylated proteins.

Purpose of the Study:

• To review the role of PIN1 in cancer development and progression.
• To discuss the potential of PIN1 inhibitors as a therapeutic strategy for cancer.

Main Methods:

• Literature review of studies on PIN1 function in cancer.
• Analysis of signaling pathways involving proline-directed phosphorylation.
• Evaluation of preclinical and clinical data on PIN1 inhibitors.

Main Results:

• PIN1 is overactivated in various cancers.
• Overactivated PIN1 promotes cancer and cancer stem cells by disrupting the balance between oncogenes and tumor suppressors.
• PIN1 inhibition has shown potential in preclinical models to restore this balance.

Conclusions:

• PIN1 plays a critical role in cancer pathogenesis.
• Targeting PIN1 with inhibitors represents a promising therapeutic avenue for improving long-term cancer treatment efficacy, particularly in solid tumors.